Back to Index
Eve E. Kelland, PhD
Assistant Professor of Research Neurology
MCH 246 Health Sciences Campus Los Angeles
+1 323 442 3036


Dr. Kelland is interested in the effect of the immune system and inflammation on cells of the nervous system (neural cells), especially those responsible for myelination and remyelination. Dr. Kelland received her formal Ph.D. training at the University of Surrey, United Kingdom, where she studied the mechanisms of glutamate and zinc toxicity in oligodendrocyte progenitor cells (the brain stem cells responsible for myelination). In 2004, she was recruited, as a postdoctoral fellow, to the University of Southern California and was appointed as an Assistant Professor of Research in the Department of Neurology in 2011.

Dr. Kelland has received grant support from the Race to Erase MS, the USC Medical Faculty Women's Association, the SC-CTSI and the Zumberge Foundation. Current research projects in Dr. Kelland’s laboratory focus on defining the effect of chemokines and chemokine receptors on the potential for neural stem cells and oligodendrocyte progenitor cells to repair types of neural damage that occur in multiple sclerosis (MS) as well as the role of the renin-angiotensin system in MS disease pathogenesis. Additional projects in Dr. Kelland’s laboratory involve the study of new drugs for MS, and whether they affect the ability of neural stem cells and oligodendrocyte progenitor cells to repair neural damage.


In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells. J Neurol Sci. 2014 Nov 15; 346(1-2):66-74. View in: PubMed

Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod. J Neuroimmunol. 2013 Oct 15; 263(1-2):108-15. View in: PubMed

The dual role of CXCL8 in human CNS stem cell function: Multipotent neural stem cell death and oligodendrocyte progenitor cell chemotaxis. Glia. 2011 Dec; 59(12):1864-78. View in: PubMed

The geometric and spatial constraints of the microenvironment induce oligodendrocyte differentiation. Proc Natl Acad Sci U S A. 2008 Sep 23; 105(38):14662-7. View in: PubMed

Measuring apoptosis in neural stem cells. Methods Mol Biol. 2008; 438:227-41. View in: PubMed

Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology. 2004 Jul; 47(1):46-64. View in: PubMed

Pyruvate limits zinc-induced rat oligodendrocyte progenitor cell death. Eur J Neurosci. 2004 Jan; 19(2):287-94. View in: PubMed

Characterisation of zinc uptake into rat cultured cerebrocortical oligodendrocyte progenitor cells. Neurosci Lett. 2003 Dec 4; 352(2):113-6. View in: PubMed

Regional mapping of low-affinity kainate receptors in mouse brain using [(3)H](2S,4R)-4-methylglutamate autoradiography. Eur J Pharmacol. 2001 Nov 23; 431(3):305-10. View in: PubMed

Group I metabotropic glutamate receptors limit AMPA receptor-mediated oligodendrocyte progenitor cell death. Eur J Pharmacol. 2001 Jul 27; 424(3):R3-4. View in: PubMed

Powered bySC CTSI